MARISSA COPELAND: Open Payments
NPI 1295183382 · ANDERSON, SC. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$883 in 63 payments from 15 companies in 2025. Trend: 2023 $1,453 · 2024 $578 · 2025 $883
Food & beverage: $883
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 21 | $197 |
| Novo Nordisk Inc | 14 | $187 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 9 | $146 |
| Lilly USA, LLC | 4 | $61 |
| AstraZeneca Pharmaceuticals LP | 3 | $46 |
| PFIZER INC. | 2 | $38 |
| Exact Sciences Corporation | 2 | $33 |
| Edwards Lifesciences Corporation | 1 | $31 |
| Lundbeck LLC | 1 | $24 |
| Novartis Pharmaceuticals Corporation | 1 | $23 |
Products named: VRAYLAR, CAPLYTA, Ozempic, Wegovy, FARXIGA, Rybelsus, MOUNJARO, ELIQUIS.
Industry payments across SC — which companies pay providers there.
